BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 210 filers reported holding BRIDGEBIO PHARMA INC in Q2 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $935,741 | -26.2% | 36,942 | -9.9% | 0.00% | -25.0% |
Q1 2024 | $1,268,091 | -24.3% | 41,012 | -1.2% | 0.00% | -33.3% |
Q4 2023 | $1,675,032 | +50.6% | 41,492 | -1.7% | 0.01% | +50.0% |
Q3 2023 | $1,112,603 | +10.6% | 42,192 | -27.8% | 0.00% | 0.0% |
Q2 2023 | $1,005,685 | +123296.9% | 58,470 | +18.8% | 0.00% | 0.0% |
Q1 2023 | $815 | +136.2% | 49,202 | +8.6% | 0.00% | +100.0% |
Q4 2022 | $345 | -99.9% | 45,317 | -10.0% | 0.00% | -33.3% |
Q3 2022 | $500,000 | -17.5% | 50,363 | -24.7% | 0.00% | 0.0% |
Q2 2022 | $606,000 | -33.8% | 66,839 | -26.0% | 0.00% | -25.0% |
Q1 2022 | $915,000 | -95.1% | 90,288 | -91.9% | 0.00% | -95.3% |
Q4 2021 | $18,500,000 | -52.8% | 1,109,233 | +32.5% | 0.09% | -58.3% |
Q3 2021 | $39,224,000 | -22.7% | 836,914 | +0.6% | 0.21% | -28.0% |
Q2 2021 | $50,722,000 | +0.5% | 832,084 | +1.5% | 0.29% | -16.4% |
Q1 2021 | $50,488,000 | -8.6% | 819,632 | +5.5% | 0.34% | -18.2% |
Q4 2020 | $55,253,000 | – | 777,031 | – | 0.42% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 6,068,125 | $60,317,000 | 40.05% |
Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $308,746,000 | 6.20% |
M28 Capital Management LP | 513,300 | $5,102,000 | 5.33% |
GREAT POINT PARTNERS LLC | 1,050,000 | $10,437,000 | 2.51% |
Octagon Capital Advisors LP | 933,743 | $9,281,000 | 1.60% |
HHLR ADVISORS, LTD. | 5,362,014 | $53,298,000 | 1.40% |
VIKING GLOBAL INVESTORS LP | 26,620,991 | $264,613,000 | 1.22% |
Cormorant Asset Management, LP | 1,469,179 | $14,604,000 | 1.02% |
Fernwood Investment Management, LLC | 204,550 | $2,033,000 | 0.86% |
TANG CAPITAL MANAGEMENT LLC | 585,424 | $5,819,000 | 0.71% |